BeOne Medicines AG (ONC)
| Market Cap | 29.34B +10.7% |
| Revenue (ttm) | 5.70B +29.9% |
| Net Income | 533.73M |
| EPS | 4.52 |
| Shares Out | 111.17M |
| PE Ratio | 58.42 |
| Forward PE | 37.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 299,593 |
| Open | 268.20 |
| Previous Close | 268.20 |
| Day's Range | 262.87 - 268.88 |
| 52-Week Range | 239.25 - 385.22 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 412.35 (+56.24%) |
| Earnings Date | Aug 5, 2026 |
About ONC
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
Analyst Summary
According to 28 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $412.35, which is an increase of 56.24% from the latest price.
News
BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
Business Wire India Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment B...
BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology ...
RSI Alert: BeOne Medicines (ONC) Now Oversold
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
BeOne Medicines Presents Promising CLL Data for Patients Over 80
BeOne Medicines Presents Promising CLL Data for Patients Over 80
BeOne Medicines (ONC) Presents Encouraging Phase 3 Data on Brukinsa for CLL
BeOne Medicines (ONC) Presents Encouraging Phase 3 Data on Brukinsa for CLL
BeOne Medicines announces presentation of Phase 3 data in CLL patients
BeOne Medicines (ONC) announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, CLL/SLL, aged 80 and older, showing sustained b...
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 datase...
BeOne Medicines AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Five solid tumor programs are prioritized for phase III, with rapid global development and robust go/no-go criteria. Financial guidance was raised following strong Q1 results, and BRUKINSA leads the BTK inhibitor market. New launches and pipeline assets show strong efficacy and safety, with innovation in bispecifics and trispecifics.
Baker Bros. Advisors LP Significantly Reduces Stake in BeOne Medicines Ltd
Baker Bros. Advisors LP Significantly Reduces Stake in BeOne Medicines Ltd
BeOne Medicines price target raised to $436 from $425 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on BeOne Medicines (ONC) to $436 from $425 and keeps an Outperform rating on the shares. At ASCO, the company…
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
BeOne Medicines NASDAQ: ONC used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company sai...
BeOne Medicines AG Transcript: Study update
Three solid tumor programs—CDK4 inhibitor in breast cancer, B7-H4 ADC in ovarian cancer, and GPC3x4-1BB bispecific in HCC—show strong efficacy and favorable safety, with all on track for registrational studies. The pipeline leverages rapid development and broad combinability.
BeOne Medicines AG Press release: Study update
BeOne Medicines AG issued a press release on June 1, 2026, disclosing material business information to investors.
BeOne Medicines AG Slides: Study update
BeOne Medicines AG has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines' ...
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pi...
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic...
BeOne Medicines (ONC) Reveals Promising HERIZON-GEA-01 Trial Results
BeOne Medicines (ONC) Reveals Promising HERIZON-GEA-01 Trial Results
BeOne Medicines’ combination shows improved survival in adenocarcinoma
BeOne Medicines (ONC) announced data from the HERIZON-GEA-01 trial, published in The New England Journal of Medicine and to be presented at the ASCO Annual Meeting on June 1 in…
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were publish...
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 4...
China AI firms Zhipu, MiniMax to join Hong Kong’s Hang Seng Tech Index
Chinese AI firms MiniMax Group and Knowledge Atlas Technology – better known as Zhipu AI – will join the Hang Seng Tech Index next month. Their inclusion follows investor criticism that the city’s pri...
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematol...
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything, a ca...
BeOne Medicines price target raised to $367 from $364 at Leerink
Leerink raised the firm’s price target on BeOne Medicines (ONC) to $367 from $364 and keeps an Outperform rating on the shares. The firm notes the company announced that the…